An international expert group convened by the American Diabetes Association proposed that the criterion for diabetes remission be an HbA1c level below 6.5%, measured at least three months after glucose-lowering drugs are stopped.
The rate of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes was 27% lower in participants with dyslipidemia randomized to fenofibrate than among those randomized to placebo.
Patients were more likely to choose more intensive care after an annual consultation if they had a high level of education, if they were concerned about illness, if they had set goals for their care, and if they had comorbid conditions.
The updates were based on findings from the industry-funded CREDENCE (Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy) trial.
The hypoglycemia risk stratification tool is based on six variables: previous episodes of hypoglycemia-related hospital utilization, insulin use, sulfonylurea use, ED use in the previous year, chronic kidney disease stage, and age.
The review included 189 randomized controlled trials that compared glucagon-like peptide-1 receptor agonists or dipeptidyl peptidase-2 inhibitors with placebo or other diabetes drugs in patients with type 2 diabetes.
Although it would seem to make sense that routine glucose self-monitoring provides better outcomes, this long-held belief is not supported by the data, said an editor's note accompanying the study.
health status, comorbid conditions, or glycemic control and highlight the fact that potential overtreatment of diabetes is a widespread issue.
The position statement recommends that physicians consider assessing cognitive capacities and symptoms of diabetes distress, depression, anxiety, and disordered eating at the initial visit and at periodic intervals.
Patients with type 1 diabetes taking dapagliflozin for 24 weeks had lower HbA1c level, body weight, and insulin dose than those on placebo, according to the industry-funded study.